ABC	activated B-cell
ALL	acute lymphoblastic leukemia
AlloSCT	allogeneic hematopoietic stem cell transplantation
ASCT	autologous stem cell transplantation
ATC	anatomical therapeutic chemical
BCL2	B-cell lymphoma 2
BCL6	B-cell lymphoma 6
BCR	Belgian Cancer Registry
BEAM	bendamustine–etoposide–AraC–methotrexate
BHS	Belgian Haematological Society
BTR	Belgian Transplant Registry
CAR-T	chimeric antigen receptor T cells
CD10	cluster of differentiation 10, neprilysin
CHOP	cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone
CNK	Code Nationa(a)l Kode
CNS	central nervous system
COO	cell of origin
DLBCL	diffuse large B-cell lymphoma
ECOG	Eastern Cooperative Oncology Group
EFS24	event-free survival at 24 months
ESR2013	age-standardized incidence rate using the European standard population of 2013
FISH	fluorescence in situ hybridization
GCB	germinal center B-cell
HD MTX	high-dose methotrexate
HDC	high-dose chemotherapy
HGBCL	high-grade B-cell lymphoma
HR	hazard ratio
IFRT	involved field radiotherapy
IHC	immunohistochemistry
IMA	Intermutualistic Agency
IPI	International Prognostic Index
IRF4	interferon regulatory factor 4
IT	intrathecal
IV	intravenous
KI-67	marker of proliferation Ki-67
LDH	lactate dehydrogenase
MCL	mantle cell lymphoma
MYC	MYC proto-oncogene, bHLH transcription factor
NCCN	National Comprehensive Cancer Network
NOS	not otherwise specified
OS	overall survival
PCNSL	primary central nervous system lymphoma
PMBCL	primary mediastinal B-cell lymphoma
PS	performance status
PTLD	post-transplant lymphoproliferative disease
R	rituximab
R-ACVBP	rituximab, adriamycine, cyclophosphamide, vincristine, bleomycine, prednisolone
R-CHOP	rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone
R-CVP	rituximab, cyclophosphamide, oncovin, prednisolone
R-DHAP	rituximab, dexamethasone, high-dose Ara-C, platinum
RT	radiotherapy
SEER	Surveillance, Epidemiology and End Results
SIR	standardized incidence ratio
WHO	World Health Organization
WSR	world standard rate
YR	years
IQR	interquartile range